Selective Serotonin Reuptake Inhibitor
Selective Serotonin Reuptake Inhibitor - most related articles:
- Paradoxical effect of certain antidepressants discovered
- Antidepressant drugs may lead to lactation difficulties in moms
- New target for antidepressants for depression and anxiety
- Antidepressants in pregnancy increase miscarriage risk
- Antidepressant may prevent heart failure
- Milnacipran for management of fibromyalgia approved
- Antidepressant and psychotherapy work for depressed teens
- Lack of evidence for antidepressants in Autism
- Positive clinical trial results of vilazodone for depression
- Brain and genes to improve anxiety treatment
Selective Serotonin Reuptake Inhibitor articlesAntidepressant may prevent heart failure
A medication usually used to help treat depression and anxiety disorders has the potential to help prevent heart failure. John Tesmer, research professor at the U-M Life Sciences Institute and professor in the Department of Pharmacology at the U-M Medical School, and his research team at the Tesmer lab found that paroxetine, a selective serotonin reuptake inhibitor (SSRI) sold under the name Paxil, inhibits G protein-coupled receptor kinase 2 (GRK2), a protein kinase that becomes over-expressed when people have heart failure.Anti inflammatory drugs reduce effectiveness of SSRI antidepressants
Anti-inflammatory drugs, which include ibuprofen, aspirin and naproxen, reduce the effectiveness of the most widely used class of antidepressant medications, the selective serotonin reuptake inhibitors, or SSRIs, taken for depression and obsessive-compulsive disorder and anxiety disorders.Lack of evidence for antidepressants in Autism
Antidepressants commonly prescribed to people with autistic spectrum disorders cannot be recommended based on current evidence, revealed by Cochrane Researchers.Antidepressant drugs may lead to lactation difficulties in moms
Women taking commonly used forms of antidepressant drugs may experience delayed lactation after giving birth and may need additional support to achieve their breastfeeding goals.Positive clinical trial results of vilazodone for depression
Clinical Data, Inc. (NASDAQ: CLDA) announced positive top-line results from the second of two Phase III trials of its investigational compound, vilazodone, for the treatment of major depressive disorder (MDD).
5 Selective Serotonin Reuptake Inhibitor articles listed above.
List health news
, Health organizations
, Health news world
, Glossary Go to top
The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
© 2015 HealthNewstrack.com
Health Newstrack - Track Health News Daily at HealthNewstrack.com. Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.